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Comparison of Symptoms, Healthcare Utilization, and
Treatment in Diagnosed and Undiagnosed Individuals
With Diarrhea-Predominant Irritable Bowel Syndrome
Gregory S. Sayuk, MD, MPH1, 2, Ray Wolf, PharmD3 and Lin Chang, MD4
OBJECTIVES:

Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by symptoms including
abdominal pain and altered bowel function. Up to 75% of individuals with IBS may be undiagnosed.
The aim of this study was to characterize symptoms, healthcare utilization, and treatments in
populations with both diagnosed and undiagnosed IBS.

METHODS:

An online survey was conducted to compare gastrointestinal (GI) symptoms, healthcare visits, wellbeing, symptom management, and treatment satisfaction in individuals with and without medically
diagnosed IBS (Rome III criteria). Symptom severity, disruptiveness, and treatment satisfaction
were rated using a 7-point scale. Adjustments to daily life were determined by predeﬁned survey
responses.

RESULTS:

A total of 1,924 individuals with a history of GI symptoms were eligible and completed the survey. Of
these, 1,094 individuals (56.9%) met the criteria for IBS; 830 individuals (43.1%) had no medical
diagnosis of IBS despite meeting diagnostic criteria. Most participants received a diagnosis from
either gastroenterologists (45%) or primary care physicians (42%). A greater percentage of diagnosed
patients had severe GI symptoms (score ≥6) vs. undiagnosed individuals (16% vs. 8%, respectively;
P<0.05); diagnosed patients were more likely to report that GI symptoms adversely affected their
quality of life. Approximately 40% of participants received IBS-related treatment from primary
care physicians; 26% and 43% of diagnosed and undiagnosed individuals, respectively, were not
receiving treatment for GI symptoms.

CONCLUSIONS: Many individuals with IBS-related symptoms have not been medically diagnosed with IBS.

IBS-related symptoms impact quality of life, yet more than one-third of individuals are not receiving
treatment for IBS.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/ajg

Am J Gastroenterol 2017; 112:892–899; doi:10.1038/ajg.2016.574; published online 17 January 2017

INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder
characterized by chronic or recurrent symptoms of abdominal
pain that is associated with altered bowel function (i.e., pain
related to defecation, changes in stool frequency, or appearance) (1–3). Additional symptoms of IBS may include straining,
fecal urgency, and bloating (1). IBS can further be subdivided by
stool consistency, namely, constipation-predominant IBS (IBS-C),

diarrhea-predominant IBS (IBS-D), or mixed bowel habit pattern
(IBS-M). Importantly, patients with IBS report reduced healthrelated quality of life (HRQOL) compared with individuals without IBS (4).
As many as 48 million individuals in the United States are
thought to be affected by IBS annually (5), yet up to 75% of
patients with IBS may lack a formal medical diagnosis of IBS (6).
Although diagnostic symptom criteria exist for IBS (1,3), they are
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mainly used in clinical research studies, rather than used routinely
in clinical practice. In a US study using a large health insurance
database, patients with IBS were most likely to receive a diagnosis from an internist (68%) rather than a gastroenterologist (13%)
(7). Hungin et al. (8) conducted a European study that surveyed
3,880 participants with IBS symptoms and suggested that primary
care physicians may have an even greater role in IBS diagnosis and
management; the authors found that most patients with medically
diagnosed IBS sought medical care from primary care physicians
(90%) rather than gastroenterologists (28%). Of symptomatic individuals lacking a medical diagnosis of IBS, Hungin et al. (8) found,
for a European population, that 37% did not receive care, whereas
55 and 12% sought medical care from primary care physicians
and gastroenterologists, respectively. A comparable, but smaller,
US community survey study conducted by the same group found
similar results (6). The reasons for the lack of a formal diagnosis of
IBS for many individuals are not entirely clear, but likely are multifactorial. Individuals with IBS symptoms often describe a range of
gastrointestinal (GI) symptoms, including reflux-like symptoms,
dyspepsia, and IBS-related symptoms (e.g., fecal urgency, bloating)
(9). IBS-D may pose a relatively greater diagnostic challenge than
the other bowel habit subtypes, as celiac disease and inflammatory
bowel disease, among other conditions, need to be considered in
patients with chronic or recurrent diarrhea (10). In fact, current
evidence suggests that celiac serologies and inflammatory markers
such as C-reactive protein and fecal calprotectin should be
obtained in these patients (11).
Previous studies have compared GI and psychologic symptoms
between individuals with IBS symptoms who seek healthcare and
those who do not; however, differences between individuals with
diagnosed and undiagnosed IBS (including those who had visited
a physician for their IBS-related symptoms) have not been well
studied. The European and US surveys performed by Hungin et al.
(6,8) were conducted >10 years ago, used older diagnostic criteria
for IBS and bowel habit subtypes, and did not focus on patients
with IBS-D.
Thus, the objective of this investigation was to compare symptom characteristics, healthcare utilization, HRQOL, treatments,
and perceived explanations for GI symptoms in patients diagnosed
with IBS-D using contemporary criteria compared with individuals who remain undiagnosed despite having sought medical attention for IBS-related symptoms.

severity of GI symptoms, number and type of healthcare visits,
general well-being, management of symptoms, and treatment
satisfaction. A point system redeemable for various rewards (e.g.,
gift cards) was used as an incentive for participation in the survey.
Participants were classified as patients with diagnosed IBS if
they indicated that a healthcare provider had diagnosed them as
having IBS (i.e., “diagnosed patients”). Participants were classified
as individuals with undiagnosed IBS-D (i.e., “undiagnosed individuals”) if their symptoms were compatible with IBS according
to Rome III criteria (1) based on their survey responses, but they
had not received a medical diagnosis of IBS. Hence, undiagnosed
individuals with IBS-D symptoms reported abdominal pain and
discomfort at least 2 to 3 days per month for at least the previous 3 months. Furthermore, these symptoms were accompanied
by more frequent bowel movements and looser stools, and individuals experienced improvement in abdominal pain or discomfort with a bowel movement. Individuals were not included
in the study if they reported constipation as “always” occurring or
if their associated stomach issues were predominantly accompanied by constipation. Individuals were also not included in the
analysis if they reported having irregular hematochezia or anorectal bleeding in the previous month or if they had previous
GI surgery.
Assessments

Symptom severity was scored on a 7-point scale (range: 1=very
mild to 7=very severe). Disruptiveness of symptoms was also
scored on a 7-point scale (range: 1=not at all disruptive to
7=extremely disruptive), as was satisfaction with current treatments (range: 1=extremely unsatisfied to 7=extremely satisfied).
Adjustments to daily living invoked to control symptoms were
determined based on 11 predefined responses, or a choice of
“other” or “none of the above” to the question: “Which, if any, of
the following things do you do in your day-to-day life in order
to manage your (IBS/stomach problems)?” Detailed information
regarding questions and response options are included in Table 1
in the Supplementary Information online.
Statistically significant differences between diagnosed and undiagnosed populations were calculated using a z-test for proportions
and only calculated as P<0.05, which was considered statistically
significant, or P≥0.05, which was considered not statistically significant.
Role of the sponsor

METHODS
Study participants

Individuals ≥18 years of age from a general US population sample who had previously responded to invitations to participate
in various surveys for two different firms and who indicated in
a profile questionnaire that they had experienced GI issues were
eligible for inclusion in the survey. An invitation to complete an
online survey was sent by e-mail to eligible individuals in the two
databases, with up to three additional e-mail reminders sent to
nonresponders. The survey was conducted between 1 September
2014 and 15 September 2014, and assessed the frequency and
Ofﬁcial journal of the American College of Gastroenterology

The study was sponsored by Salix Pharmaceuticals, which had a
role in study design and data analysis.

RESULTS
Study participants

A total of 126,057 individuals pooled from 2 separate groups
of potential respondents were sent an invitation by e-mail to
participate in the survey. Of the 23,707 individuals (18.8%)
who accessed the link to the survey, 1,924 (1.5%) completed the
survey, thus meeting the eligibility criteria for inclusion in the
The American Journal of GASTROENTEROLOGY
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Table 1. Population demographics and symptom history
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Individuals, N (%)

Parameter

Diagnosed with
IBS-D (n=1,094)

Undiagnosed
(n=830)

Male/female (%)

241:853a (22:78a)

299b:531 (36b:64)

Age range, years (n, %)
18–39

416 (38)

332 (40)

40–59

437 (40)

398 (48)b

≥60

241 (22)a

100 (12)

Race/ethnicity (n, %)
White

1,017 (93)a

714 (86)

Black

33 (3)

50 (6)b

Hispanic/Latino

33 (3)

42 (5)

Asian-American/Asian

22 (2)

33 (4)b

Other ethnicity

11 (1)

25 (3)

<5

272 (25)

546 (66)b

5–10

218 (20)a

134 (16)

a

604 (55)

150 (18)

33 (3)

50 (6)b

Symptom duration, years (n, %)

≥10
Symptom intensity (n, %)
Mild (score, 1–2)
Moderate (score, 3–5)

886 (81)

714 (86)

a

66 (8)

Symptoms <5 years

60 (22)a,c

33 (6)d

Symptoms 5–10 years

83 (38)a,e

23 (17)f

Severe (score, 6–7)

175 (16)

Consulted ≥3 physicians (n, %)

Symptoms ≥10 years

a,g

302 (50)

44 (29)h

Consultation with gastroenterologist (n, %)
Symptoms <5 years

139 (51)a,c

137 (25)d

Symptoms 5–10 years

122 (56)

a,e

40 (30)f

Symptoms ≥10 years

405 (67)a,g

68 (45)h

IBS-D, diarrhea-predominant irritable bowel syndrome.
a
P<0.05 vs. undiagnosed.
b
P<0.05 vs. diagnosed.
c

n=272.
n=546.
e
n=218.
f
n=134.
g
n=604.
h
n=150.
d

study (Supplementary Figure S1 online). Of these individuals,
1,094 (56.9%) met the criteria for an IBS-D diagnosis; despite
meeting the Rome III criteria for IBS-D, 830 individuals (43.1%)
had not received a medical diagnosis of IBS. In the undiagnosed
group, 53% of individuals reported that they had never spoken
with a physician regarding their stomach problems.
Of the diagnosed patients, 45% and 42% of patients received a
diagnosis from either a gastroenterologist or a primary care physiThe American Journal of GASTROENTEROLOGY

cian, respectively. Internists diagnosed 11% of patients with IBS-D.
Compared with undiagnosed individuals, diagnosed patients were
more commonly white and female (P<0.05; Table 1). Older individuals (≥60 years of age) were also more likely to be diagnosed
with IBS. Furthermore, diagnosed patients had consulted a greater
number of physicians and had more GI consultations as compared
with undiagnosed individuals (P<0.05 for all comparisons), with the
percentage of diagnosed and undiagnosed individuals consulting
healthcare providers increasing with a longer duration of symptoms.
GI symptom history and impact on HRQOL

A significantly greater percentage of diagnosed patients had GI
symptoms for ≥10 years compared with undiagnosed individuals
(55% vs. 18%, respectively; P<0.05). Conversely, a significantly
greater percentage of undiagnosed individuals had symptoms for
<3 years compared with diagnosed patients (51% vs. 14%, respectively; P<0.05). Diagnosed patients were twice as likely to have
severe GI symptoms (i.e., severity score, 6 or 7) than undiagnosed
individuals (16% vs. 8%, respectively; P<0.05), whereas undiagnosed individuals were significantly more likely to have mild
symptoms (i.e., severity score, 1 or 2) compared with diagnosed
patients (6% vs. 3%, respectively; P<0.05). A greater percentage
of diagnosed patients had more severe symptoms compared with
individuals in the undiagnosed group for discomfort/pain (diagnosed, 36% vs. undiagnosed, 24%), diarrhea (52% vs. 29%), loose/
mushy stools (49% vs. 29%), urgency (61% vs. 41%), and bloating
(26% vs. 20%); P<0.05 for all comparisons (Figure 1a).
Diagnosed patients had more disruptive IBS-associated symptoms than individuals in the undiagnosed group, including discomfort/pain (32% vs. 27%), diarrhea (61% vs. 40%), loose/mushy
stools (44% vs. 27%), and urgency (64% vs. 46%); P<0.05 for all
comparisons (Figure 1b). Bloating occurred in a comparable
percentage of individuals (19% vs. 18%). Yet, undiagnosed individuals had more “confounder” symptoms (i.e., heartburn, gastric
reflux, constipation) than diagnosed patients. When experiencing GI symptoms of pain or discomfort and diarrhea, diagnosed
patients reported IBS-associated symptoms (e.g., bowel movement urgency, bloating, nausea) “always or most of the time” with
greater frequency than undiagnosed individuals (Figure 2).
In addition, both diagnosed and undiagnosed patients
reported that HRQOL was adversely impacted by GI symptoms
(Supplementary Table S2 online). However, a significantly greater
percentage of diagnosed patients than undiagnosed individuals
reported cancelling or changing plans at the last minute (52% vs.
39%, respectively), premedicating with antidiarrheal agents (50%
vs. 33%), and avoiding food consumption before important events
(52% vs. 39%), events with poor bathroom access (e.g., outdoor
activity; 42% vs. 27%), work activities (38% vs. 28%), or dinner or
social events with friends (34% vs. 23%), because of symptoms of
IBS (P<0.05 for all comparisons).
Management of GI symptoms

Diagnosed patients reported using a greater mean number of
treatments in the past compared with undiagnosed individuals
(4.9 vs. 3.4, respectively), including in the past 3 months (2.6 vs.
VOLUME 112 | JUNE 2017 www.nature.com/ajg
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Figure 1. Severity and disruptiveness of bowel movement characteristics. Severity (a) was determined by a score of 6 or 7 on a 7-point scale (range:
1=very mild to 7=very severe). Disruptiveness (b) was determined by a score of 6 or 7 on a 7-point scale (range: 1=not at all disruptive to 7=extremely
disruptive). aP<0.05 vs. undiagnosed group.

100

Diagnosed (n=1,094)
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80

64a
60

41
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Urgency

Bloating

Nausea
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Fatigue/tiredness

Heartburn/
gastric reflux

Figure 2. Additional symptoms experienced “always or most of the time.” aP<0.05 vs. undiagnosed group.

2.1, respectively; Table 2). However, few individuals with either
diagnosed or undiagnosed IBS reported satisfaction with treatment
(20% vs. 18%, respectively). A significantly greater percentage of
Ofﬁcial journal of the American College of Gastroenterology

diagnosed patients reported satisfaction with specific treatments
than undiagnosed individuals, notably antidiarrheals (30% vs.
24%, respectively; P<0.05) and dietary adjustments (26% vs. 20%;
The American Journal of GASTROENTEROLOGY
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Table 2. Treatments administered to help manage symptoms of irritable bowel syndrome

FUNCTIONAL GI DISORDERS

Individuals, N (%)
b

Current treatments
Treatment with recommendation score and quality of
evidence (in brackets)a

Past treatments

Diagnosed with IBS-D
(n=1,094)

Undiagnosed
(n=830)

Diagnosed with IBS-D
(n=1,094)

Undiagnosed
(n=830)

175 (16)c

66 (8)

317 (29)c

133 (16)

c

Level 2 recommendations
Antidepressants (2A)
Bulking agents or ﬁber supplements (2B)

c

219 (20)

75 (9)

558 (51)

216 (26)

Antibiotics (2B)

33 (3)

25 (3)

153 (14)

100 (12)

Alosetron (2B)

11 (1)

0 (0)

44 (4)

8 (1)

c

c

Antispasmodics (2C)

131 (12)

17 (2)

328 (30)

33 (4)

Probiotics (2C)

372 (34)c

199 (24)

689 (63)c

349 (42)

Dietary manipulation (2D)

459 (42)c

307 (37)

755 (69)c

481 (58)

Psychological therapies to reduce stress (2D)

c

66 (6)

c

42 (5)

164 (15)

75 (9)

394 (36)c

208 (25)

711 (65)c

382 (46)

306 (28)

Level 1 recommendation of insufﬁcient evidence to recommend use
Antidiarrheals (1D)
No recommendation provided; not evaluated
324 (39)d

667 (61)

498 (60)

Lifestyle adjustments to reduce stress (NA)

c

252 (23)

141 (17)

c

449 (41)

232 (28)

Incorporation of more exercise into routine (NA)

186 (17)c

100 (12)

372 (34)c

183 (22)

2.6

2.1

4.9

3.4

OTC agents for upset stomach (NA)

Treatments, mean

IBS-D, diarrhea-predominant irritable bowel syndrome; NA, not applicable; OTC, over the counter.
a
Scoring of recommendations and quality of evidence based on GRADE approach: 1=strong recommendation for or against use; 2=weak recommendation for or against
use; A=high quality of evidence; B=moderate quality of evidence; C=low quality of evidence; D=very low quality of evidence. Recommendation and quality of evidence
data from Ford et al. (2).
b
Used within the past 3 months.
c
P<0.05 vs. undiagnosed.
d
P<0.05 vs. diagnosed.

P<0.05). Furthermore, diagnosed patients were significantly more
likely to have received antidepressants or psychologic therapies
compared with undiagnosed individuals (antidepressants, 29%
vs. 16%, respectively; psychological therapies, 15% vs. 9%; P<0.05
for both comparisons). In addition, diagnosed patients were more
likely to report adjustments to daily activities as a result of GI
symptoms compared with undiagnosed individuals (Table 3).
The largest share of participants received treatment for their
IBS symptoms from primary care physicians (41% of diagnosed
patients and 38% of undiagnosed individuals). Of these, internists
treated 8% and 6% of diagnosed and undiagnosed individuals for
IBS symptoms, respectively (P<0.05). A significantly greater percentage of diagnosed patients received treatment from a gastroenterologist compared with undiagnosed individuals (23% vs. 9%,
respectively; P<0.05). In all, 26% of diagnosed patients and 43% of
undiagnosed individuals were currently not receiving treatment
for their IBS symptoms.
Perceptions about etiology of IBS symptoms

More than half of diagnosed patients believed that stress (54%)
and sensitivities to specific foods (52%) caused IBS as compared
The American Journal of GASTROENTEROLOGY

with 39% and 34% of undiagnosed individuals, respectively
(P<0.05 for both comparisons; Figure 3). Furthermore, diagnosed patients were significantly more likely than undiagnosed
individuals to believe anxiety (45% vs. 31%, respectively), genetics
(31% vs. 17%, respectively), and/or imbalances in the gut microbiota (“imbalance of bacteria within my stomach or gut”; 23%
vs. 18%, respectively) caused IBS (P<0.05 for all comparisons).
Finally, 29% and 16% of diagnosed and undiagnosed participants,
respectively, believed “this is just the way my body works” was a
cause for IBS (P<0.05).
Almost half (47%) of undiagnosed individuals reported speaking with their physician about stomach problems, with the majority of these individuals speaking with 1 or 2 physicians (54% and
33%, respectively). Most undiagnosed individuals had considered
that they might have IBS (67%; Supplementary Figure S2 online).
However, 61% of undiagnosed individuals never considered they
might have the IBS-D form of IBS. Another 20% of undiagnosed
individuals reported that they had considered that they might have
IBS-D, but had never asked their physician about it, and 19% of
undiagnosed individuals reported speaking with their physician,
who stated that they did not have IBS-D.
VOLUME 112 | JUNE 2017 www.nature.com/ajg

Table 3. Lifestyle modiﬁcations used to manage symptoms of
irritable bowel syndrome
Positive response to “Which, if any,
of the following things do you do in
your day-to-day life in order to manage your (IBS/stomach problems)?”

Individuals, N (%)
Diagnosed with
IBS-D (n=1,094)

Undiagnosed
(n=830)

Avoid foods that I think will upset my
stomach

799 (73)a

506 (61)

Always know where bathrooms are
located

733 (67)a

407 (49)

Keep OTC medications or supplements handy at all times

569 (52)a

374 (45)

Avoid stressful situations

350 (32)a

199 (24)

350 (32)

a

183 (22)

Carry wipes when you’re on the go

252 (23)

a

133 (16)

Avoid drinking alcohol

219 (20)a

133 (16)

Put off or avoid intimacy with a partner

197 (18)

a

116 (14)

Wear different clothes such as oversized, looser, or dark-colored items

186 (17)

116 (14)

Carry an extra set of clothing

142 (13)a

66 (8)

44 (4)

25 (3)

Always stay near a bathroom

Avoid exercise

a

Other

55 (5)

None of the above

44 (4)

83 (10)b

3.7

2.9

Current lifestyle adjustments, mean

17 (2)

IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel
syndrome; OTC, over the counter.
a
P<0.05 vs. undiagnosed.
b
P<0.05 vs. diagnosed.

Diagnosed and undiagnosed participants reported that their
physicians had described a mean of 3.1 and 2.3 factors, respectively, that may be contributing to their IBS/stomach problems.
Only 15% of participants reported that they were provided only
one cause of their IBS/stomach problems by physicians. Factors
provided by physicians varied significantly between diagnosed
and undiagnosed participants and included stress or anxiety (67%
vs. 37%, respectively; P<0.05), specific food sensitivities (58% vs.
32%, P<0.05), gut microbiota imbalances (34% vs. 16%; P<0.05),
genetics (32% vs. 14%; P<0.05), and “this is just the way my body
works” (21% vs. 7%; P<0.05).

DISCUSSION
In this study, we report on a cohort of internet survey responders who met Rome III criteria for IBS-D, comparing the clinical
features of participants formally “diagnosed” with IBS-D with
those of “undiagnosed” individuals similarly affected by IBS-D
symptoms. The survey revealed that more than two in every five
individuals experiencing IBS-D symptoms had not been formally
diagnosed with the condition.
Although this undiagnosed group reflects a substantial portion
of individuals reporting IBS-like symptoms, a smaller US study
Ofﬁcial journal of the American College of Gastroenterology

by Hungin et al. (6) previously reported that most individuals
(>75%) meeting IBS diagnostic criteria had not been formally
diagnosed by a physician with IBS (any subtype). However, only
53% of those not medically diagnosed with IBS had visited a medical professional at some point for their condition; this rate is in
line with that observed in the current study. Although this study
employed different study methodologies and criteria to define
IBS, and limited its focus to diarrhea-predominant symptoms, we
interpret this improvement in rates of IBS diagnosis to, in part,
reflect an enhanced awareness of IBS on behalf of patients and
physicians alike. Earlier research has suggested that gastroenterologists have reasonable familiarity with Rome diagnostic criteria, whereas general practitioners may be less familiar with these
criteria (12,13), and perhaps less comfortable in making an IBS
diagnosis based on symptom-based criteria alone (14). This latter
observation might continue to pose a challenge in establishing
definitive IBS diagnoses, particularly in light of these data suggesting that less than half of potential IBS diagnoses are made by
gastroenterologists. Gastroenterologist consultation ultimately
may be an important step in expediting IBS diagnoses; in those
experiencing IBS-D symptoms for <5 years in this survey, gastroenterologist consultations were reported by IBS-D-diagnosed
individuals at rates double those of undiagnosed participants
(51% vs. 25%, respectively). It should be acknowledged that the
IBS-D-diagnosed patients generally utilized more healthcare
services, with higher rates of physician consultation (even when
stratified by duration of symptoms), and significantly greater
rates of GI/abdominal surgery. These health-seeking behaviors
of IBS-D-diagnosed patients alone may have facilitated physician
diagnoses.
Individuals diagnosed with IBS-D in this study reported more
severe and disruptive symptoms, particularly abdominal pain and
alterations in bowel frequency/consistency, and endorsed greater
impact of their symptoms on HRQOL. Chronic symptoms without revelation of an organic process should further facilitate an
IBS diagnosis, and, indeed, more than half of IBS-diagnosed participants in this survey reported having symptoms for >10 years;
conversely, 51% of undiagnosed individuals reported symptoms
of <3 years in duration. Undiagnosed individuals in this study
reported proportionately greater numbers of GI symptoms not
typically associated with IBS-D, such as heartburn/GI reflux disease, that may have further confounded physicians’ abilities to
confidently diagnose IBS-D. Taken together, these data highlight
the importance of maintaining a high index of suspicion in establishing a diagnosis of IBS, particularly in cases with milder symptoms of shorter durations, or in the context of less typical symptom
presentations.
The data suggest that formal IBS-D diagnoses may be important for two reasons. First, an IBS diagnosis may facilitate the dialogue between the patient and physician about treatment options.
Patients diagnosed with IBS-D were offered more treatments
and were found to have greater access to evidence-based, proven
therapies. Indeed, a greater percentage of patients with diagnosed
IBS received prescription treatment for symptoms compared
with undiagnosed individuals with IBS symptoms (50% vs. 30%,
The American Journal of GASTROENTEROLOGY

897

FUNCTIONAL GI DISORDERS

IBS in Diagnosed Vs. Undiagnosed Individuals

898

Sayuk et al.

100

Diagnosed (n=1,094)
Undiagnosed (n=830)

Individuals (%)

60

54a

52a
39

40

45a
34

31a

31

29a
17

20

23a
16

19

18

25b

19b
12

12

18b

17b

11

9 11

6 6
re
s

y

su
m
en

vi
ro
n
En

Ea

tin
g

at

ce

rta
in

ta
l

ex

tim
es

po

of

Ag

da

in
g

s
ge
an
ch
al

H
or
m
on

La

ck

of

Po

ex

or

er
ci
se

di
et

ce
im
ba

m
ic
ro
b
G
ut

m
y
w
ay

io
ta

bo

dy

ge
m
ily
tt
he
Th

is

is

ju
s

la
n

w
or
ks

ne

tic
s

xi
et
y
Fa

ns
se
od
Fo

An

iti
vi
tie
s

s

0

St
re
s

FUNCTIONAL GI DISORDERS

80

Figure 3. Participant perceptions of irritable bowel syndrome (IBS) etiology. This ﬁgure shows the percentage of individuals responding “deﬁnitely a cause”
to the question “To the best of your knowledge, which of the following do you believe are causing your IBS/stomach problems?”. aP<0.05 vs. undiagnosed
group. bP<0.05 vs. diagnosed group.

respectively) (8). Although dietary modification and antidiarrheals were tried at some point by approximately half to two-thirds
of individuals with undiagnosed or diagnosed IBS-D, respectively,
antibiotics, antispasmodics, and serotonin (5-hydroxytryptamine
type 3) antagonists that have beneficial effects in IBS-D (2,15)
were tried in only a small subset of patients. Patients diagnosed
with IBS were also significantly more likely (P<0.05) in this study
to manage symptoms by engaging in lifestyle modifications for
which there are data supporting their use, such as abstaining from
problematic foods and avoidance of stressful situations (16,17).
Minimizing the use of prescription medications, when possible,
has been suggested for patients with IBS, as patient education
and reassurance are considered key aspects of disease management (18). Symptom severity clearly is an important factor influencing therapeutic interventions; a previous study demonstrated
that patients with severe IBS had a greater mean number of physician visits compared with patients with mild or moderate IBS
(19). Results of this same study indicated that patients with severe
IBS were receiving a greater mean number of medications compared with patients with mild or moderate IBS (2.5 vs. 1.6 and 1.9,
respectively) (19).
The second reason why a formal IBS-D diagnosis is valuable is
that patients with this distinction appeared to be better informed
about IBS pathophysiology, reporting explanations for their symptoms that are more scientifically derived (e.g., diet, genetics, and
intestinal microbiota) compared with undiagnosed individuals.
Conversely, one-third of those without an IBS-D diagnosis reported
that they had been provided no explanation by their healthcare
provider for their GI symptoms. Once established, a diagnosis enables the symptomatic individual to seek out additional informational and support resources; such knowledge is central to patient
empowerment strategies that have recently proven useful in the
management of a variety of chronic pain conditions (20,21) and
may similarly enhance IBS-D treatment outcomes.
The American Journal of GASTROENTEROLOGY

Limitations of this study include those inherent to any surveybased design (e.g., potential for sampling and recall bias). Recall
bias may play a role in reporting of symptom severity (22), and
comorbid conditions could potentially influence recall of symptom severity (22). The cross-sectional nature of the study clearly
does not allow for the investigation of causal relationships, and
the analyses do not allow one to entirely separate the influences
of symptom severity and IBS diagnosis. This study also did
not comprehensively assess for comorbid functional disorders
or structural diagnoses; without access to the patient medical
records, physician diagnoses of IBS could not be confirmed.
Nevertheless, this study employed measures that were both reliable and validated; the study also successfully highlights several
important clinical distinctions between “real-world” samples
of symptomatic individuals with or without an IBS diagnosis
(23). Although we only studied patients with IBS-D symptoms
using Rome III criteria, we anticipate that similar findings likely
would be present in IBS patients with constipation and mixed
bowel patterns, and largely would extrapolate to the new Rome
IV criteria (3), although this needs to be studied.
In conclusion, a substantial percentage of individuals meeting
Rome III criteria for IBS-D have not been formally diagnosed with
IBS. Individuals with undiagnosed IBS generally experience milder
and less disruptive GI symptoms, experience fewer supportive
symptoms of IBS (e.g., urgency, bloating), and report symptoms
for fewer years than their counterparts diagnosed with IBS-D;
all these factors may challenge the clinician’s ability to make a
definitive IBS-D diagnosis, particularly in the primary care setting.
Nevertheless, it is important that providers maintain an appropriate index of suspicion in diagnosing IBS, as clinical recognition of this condition may enhance patient insight into potential
etiopathologic factors that trigger symptoms (i.e., diet, stress) and
may facilitate physician implementation of more proven, evidencebased treatment approaches.
VOLUME 112 | JUNE 2017 www.nature.com/ajg
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Study Highlights
WHAT IS CURRENT KNOWLEDGE

✓ Symptoms of irritable bowel syndrome (IBS) adversely
impact quality of life.
✓ Many individuals with diarrhea-predominant IBS (IBS-D)
remain undiagnosed.
✓ Symptoms, healthcare utilization, and treatments in

individuals with diagnosed or undiagnosed IBS-D are not
well characterized.

WHAT IS NEW HERE

✓ Severity of symptoms and impact on quality of life is

greater in patients with diagnosed IBS compared with
those who are undiagnosed.

✓ One-third of individuals with undiagnosed IBS reported
that they had been provided no explanation for their GI
symptoms by their healthcare provider.

✓ Nearly two-thirds of undiagnosed individuals had never
considered that they might have IBS-D.
✓ Only a small subset of individuals with IBS-D have been

treated with medications that have shown efﬁcacy in IBS-D
clinical trials.
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